Allergy Therapeutics (AGY) — Cash Flow Quality Index
Allergy Therapeutics (AGY) has a Cash Flow Quality Index of 0.56x as of December 2021. Operating cash flow of GBX3.71 Million is below net income of GBX6.67 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how well can Allergy Therapeutics service its debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Allergy Therapeutics Cash Flow Quality Index (2003–2021)
Historical Cash Flow Quality Index for Allergy Therapeutics across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see AGY cash flow conversion.
Annual Cash Flow Quality Index for Allergy Therapeutics (2003–2021)
Year-by-year earnings quality comparison for Allergy Therapeutics.
| Year | Quality Index | Operating CF (GBX) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 2.95x | GBX8.52 Million | GBX2.89 Million | ▲ +69.7% |
| 2020 | 1.74x | GBX12.28 Million | GBX7.06 Million | ▲ +7.7% |
| 2019 | 1.62x | GBX5.60 Million | GBX3.47 Million | ▼ -94.4% |
| 2015 | 28.92x | GBX3.12 Million | GBX108.00K | ▲ +886.1% |
| 2014 | 2.93x | GBX2.17 Million | GBX741.00K | ▼ -47.9% |
| 2013 | 5.63x | GBX2.43 Million | GBX432.00K | ▲ +25.1% |
| 2012 | 4.50x | GBX2.88 Million | GBX640.00K | ▲ +125.5% |
| 2011 | -17.63x | GBX-2.03 Million | GBX115.00K | ▼ -1607.8% |
| 2010 | 1.17x | GBX1.70 Million | GBX1.46 Million | ▼ -4.6% |
| 2004 | 1.22x | GBX1.91 Million | GBX1.56 Million | ▼ -21.7% |
| 2003 | 1.56x | GBX2.10 Million | GBX1.34 Million | — |